Abstract

Poor sensitivity of sputum conversion for monitoring tuberculosis (TB) treatment that makes identification of a non-sputum-based biomarker is urgently needed. Monitoring biomarkers in TB treatment is used to decide whether critical thresholds have been reached and helps clinicians to conclude the therapeutic success. In this mini review, we highlight recent studies on omics-related contributes to identifying of a novel biomarker as surrogate markers for the cure and predicting future reactivation risk following TB treatment. We catalogue the studies published to seek the progress made in transcriptomics, proteomics, and metabolomics in pulmonary TB. We also discuss how integrative multi-omics data will provide further understanding and effective TB treatment, such as revealing the interrelationships at multiple molecular levels, facilitating the identification of biologically interconnected processes, and accelerating precision medicine in TB treatment. However, proper validation in prospective longitudinal studies with long-term follow-up and outcome assessment must be conducted before the biomarkers are utilized in clinical practice.

MeSH

Sputum, Biomarkers, Tuberculosis, Therapeutics, Precision Medicine

Cited by

• Biomarker discovery for tuberculosis using metabolomics. Front Mol Biosci, 2023
• New Insights into Biomarkers for Evaluating Therapy Efficacy in Pulmonary Tuberculosis: A Narrative Review. Infect Dis Ther, 2023
• Advancing personalized medicine for tuberculosis through the application of immune profiling. Front Cell Infect Microbiol, 2023
• C1q and HBHA-specific IL-13 levels as surrogate plasma biomarkers for monitoring tuberculosis treatment efficacy: a cross-sectional cohort study in Paraguay. Front Immunol, 2024
• Bioinformatics Analysis to Uncover the Potential Drug Targets Responsible for Peptidoglycan and Lysine Biosynthesis. Bioinform Biol Insights, 2023
• Research progress of single-cell sequencing in tuberculosis. Front Immunol, 2023